1997 smiled on drug approvals, sales and prospects

Article Abstract:

The pharmaceutical industry's strong performance in 1997 is expected to continue into 1998, with predictions setting sales growth at 13% and totalling $81.3 billion. In 1997, sales rose 12%, 39 new drugs were approved and Congress renewed the user fees program, which helps defray Food and Drug Administration review costs. The mean drug approval period was also reduced to a record low of 16.2 months.

Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Pharmaceutical industry, Drugs, Forecasts and trends

---

Tertiary center monitors rural patients via phone line

Article Abstract:

Cardiac patients in Utah's rural Allen Memorial hospital are being monitored in real-time at a tertiary hospital 250 miles away. The system uses a high-capacity telephone line to provide live data. Allen Memorial was able to retain patients who otherwise would have been transferred, saving the hospital around $85,000. Hospital officials hope the system will attract more physicians to the area.

Hospitals, Care and treatment, Telecommunications systems, Cardiac patients, Telemedicine

---

Similar abstracts:

• Abstracts: Carbamazepine. The role of EEGs in the treatment and prognosis of epilepsy. The importance of brand continuity in epilepsy drugs
• Abstracts: Observational studies of drug safety--Aprotinin and the absence of transparency. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
• Abstracts: Diversity in medicine. Erythropoietin, the FDA, and oncology. The age of teleradiology
• Abstracts: Taking aim at handgun violence. New focus placed on von Willebrand disease
• Abstracts: Medical genetics. The Multifaceted Challenges of Proteus Syndrome. Diagnosis of X-linked adrenal hypoplasia congenita by mutation analysis of the DAX1 gene

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.